The vaccine, produced by the Cuban Finly Institute, has been tested on 120 volunteers aged over 17 at the Matola Primary Teachers Training Institute and at the Industrial and Commercial School, who had a 30 day clinical follow up.
According to the Mozambican Health Ministry's recent findings, the vaccine is safe and had an efficacy of 97.4 per cent, assessing by its capacity to induce a significant immunity response on the volunteers who received it.
But the ministry says that these results do not mean that the vaccine may now be administered massively for the control of the disease, because, according to the international norms, it has yet to be tested in lower age groups to reconfirm its safety and efficacy.
"After that, its efficacy will have to be tested in clinical tests to verify if the already found immune response can result in a significant response in an area infected with cholera", explains the ministry in a press release received by AIM on Tuesday.
Subsequent tests are under preparation and should take place within the next two years.
The undertaken tests were to verify the safety and the capacity of the vaccine to produce immunity in individuals living in a country where cholera is an endemic disease, such as Mozambique.
The drug had already been tested in different situations involving volunteers in Cuba, and Equator, where the results showed its safety and good response in terms of immunity generation.
SOURCE: AIM
